Clinicians should consider these findings when using atypical antipsychotics in patients at risk for pneumonia.
All articles by Laura Stiles
Researchers assessed pooled randomized clinical trial data (NAVIGATE I and II; N5641) to examine the change in SF-36v2 and SF-6D from baseline to the end of double blind and to the end of the studies.
Prior to this expanded indication, patients with this challenging, rare disease did not have an FDA-approved treatment option.
Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.